Quantcast

Industry news that matters to you.  Learn more

Study Shows that an FDA-cleared Biomarker can Help to Reduce ADHD Overdiagnosis

NEBA Health recently announced that Brain and Behavior has published validation results for the first biomarker cleared by FDA to assist a clinician in ADHD evaluation. Of particular note, the study shows that this brainwave-based test, NEBA, can reduce overdiagnosis by identifying children whose ADHD-like symptoms may be better explained by another condition.

Researchers Find That Tumor DNA and Cells in the Blood Can Be Used to Diagnose Prostate Cancer and Drug Resistance in Breast Cancer

Last month, the “Molecular Diagnostics” issue of Clinical Chemistry, the journal of AACC, featured new research on a genetic test for prostate cancer that could replace the unreliable prostate specific antigen (PSA) test, as well as a more accurate test for breast cancer drug resistance. Both tests could help patients receive more targeted treatment for prostate and breast cancer, which in the U.S. are the second leading causes of cancer death in men and women, respectively.

Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, recently announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.

Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test

Biocartis and VIB recently announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.

BIDMC Researchers Identify Possible Biomarker for Parkinson’s Disease

Although Parkinson’s disease is the second most prevalent neurodegenerative disorder in the U.S., there are no standard clinical tests available to identify this widespread condition. As a result, Parkinson’s disease often goes unrecognized until late in its progression, when the brain’s affected neurons have already been destroyed and telltale motor symptoms such as tremor and rigidity have already appeared.